OncoMatch/Clinical Trials/NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Official title: A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies
Is NCT05006716 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies Tacabrutideg for b-cell malignancy.
Treatment: Tacabrutideg — Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: Bruton tyrosine kinase inhibitor
Participants who have previously received a covalently-binding Bruton´s tyrosine kinase (BTK) inhibitor (BTKi) in any line of therapy must have received treatment with the BTK inhibitor for ≥ 8 weeks (unless reason for discontinuation is intolerance)
Must have received: Bruton tyrosine kinase inhibitor — MCL, expansion cohorts (Phase 2)
participants with MCL enrolling in the expansion cohorts (Phase 2) must have been treated with a BTKi in a prior line of therapy
Must have received: Bruton tyrosine kinase inhibitor — CLL/SLL, expansion cohorts (Phase 2)
CLL/SLL participants, in addition to being treated with a BTKi in a prior line of therapy, must also have received a Bcl-2 inhibitor in a prior line of therapy as well (Phase 2)
Must have received: Bcl-2 inhibitor — CLL/SLL, expansion cohorts (Phase 2)
CLL/SLL participants, in addition to being treated with a BTKi in a prior line of therapy, must also have received a Bcl-2 inhibitor in a prior line of therapy as well (Phase 2)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama At Birmingham Hospital · Birmingham, Alabama
- Mayo Clinic Phoenix · Phoenix, Arizona
- Honor Health Research Institute · Scottsdale, Arizona
- University of Arizona Cancer Center · Tucson, Arizona
- University of California San Diego (Ucsd) Moores Cancer Center · La Jolla, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05006716 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received Bruton tyrosine kinase inhibitor and Bruton tyrosine kinase inhibitor.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify